HC Wainwright Issues Positive Outlook for LXRX Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities researchers at HC Wainwright increased their Q2 2026 earnings estimates for shares of Lexicon Pharmaceuticals in a research note issued on Friday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.05) per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.16) EPS, FY2028 earnings at ($0.17) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at ($0.10) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $0.00 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.04. The business had revenue of $21.10 million for the quarter, compared to the consensus estimate of $9.79 million. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%.

A number of other brokerages also recently commented on LXRX. Citigroup upped their target price on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.55.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock opened at $2.31 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 18.80 and a quick ratio of 18.77. The company has a market capitalization of $1.03 billion, a P/E ratio of -33.00 and a beta of 0.97. The company’s 50-day simple moving average is $1.68 and its two-hundred day simple moving average is $1.46. Lexicon Pharmaceuticals has a one year low of $0.51 and a one year high of $2.47.

Insider Activity

In other Lexicon Pharmaceuticals news, Director Raymond Debbane acquired 100,000 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were purchased at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the purchase, the director owned 1,904,186 shares in the company, valued at approximately $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have purchased 252,000 shares of company stock worth $369,980 in the last 90 days. 14.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Hudson Bay Capital Management LP acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at approximately $26,000. Security National Bank of Sioux City Iowa IA acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $31,000. Leonteq Securities AG acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $34,000. EntryPoint Capital LLC acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $39,000. Finally, Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $42,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

More Lexicon Pharmaceuticals News

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Citigroup raised its price target on Lexicon Pharmaceuticals from $2.30 to $3.10 and kept a buy rating, signaling more upside potential for NASDAQ: LXRX. Article: Citigroup raises price target on Lexicon Pharmaceuticals
• Positive Sentiment: HC Wainwright maintained a buy rating and $6.00 price target while raising longer-term EPS estimates for FY2026, FY2028, FY2029, and FY2030, suggesting improving outlook beyond the near term for NASDAQ: LXRX.
• Neutral Sentiment: HC Wainwright also cut its Q3 and Q4 2026 EPS estimates, showing that near-term profitability expectations remain under pressure even as the longer-term view improved for NASDAQ: LXRX.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.